4.1 Review

Atopic dermatitis

Journal

ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
Volume 14, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13223-018-0281-6

Keywords

Atopic dermatitis; Diagnosis and management; Emollients; Skin care practices; Topical corticosteroids; Topical calcineurin inhibitors

Funding

  1. AstraZeneca
  2. Boehringer Ingelheim
  3. CSL Behring Canada Inc.
  4. MEDA Pharmaceuticals Ltd.
  5. Merck Canada Inc.
  6. Pfizer Canada Inc.
  7. Shire Pharma Canada ULC
  8. Stallergenes Greer Canada
  9. Takeda Canada
  10. Teva Canada Innovation
  11. Aralez Tribute
  12. Pediapharm

Ask authors/readers for more resources

Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of affected individuals as well as their families. Although the pathogenesis of the disorder is not completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient's history and clinical manifestations. Successful management of the disorder requires a multifaceted approach that involves education, optimal skin care practices, anti-inflammatory treatment with topical corticosteroids and/or topical calcineurin inhibitors, the management of pruritus, and the treatment of skin infections. Systemic immunosuppressive agents may also be used, but are generally reserved for severe flare-ups or more difficult-to-control disease. Topical corticosteroids are the first-line pharmacologic treatments for AD, and evidence suggests that these agents may also be beneficial for the prophylaxis of disease flare-ups. Although the prognosis for patients with AD is generally favourable, those patients with severe, widespread disease and concomitant atopic conditions, such as asthma and allergic rhinitis, are likely to experience poorer outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available